Longeveron’s Laromestrocel Fails HLHS Phase 2b Endpoint; Company Explores Strategic Options
On September 16, 2026, Longeveron reported that laromestrocel failed to meet the Month-12 primary endpoint for change from baseline in right ventricular ejection fraction in the Phase 2b ELPIS II trial in infants with hypoplastic left heart syndrome; the intent-to-treat least-squares mean difference between treatment groups was −0.7 percentage points (95% CI: −7.3 to 5.9; p=0.8336). Longeveron said it would continue analyzing exploratory endpoints and discuss a potential path forward with the FDA, while implementing cash-conservation measures and exploring strategic options with an investment bank.
The supplied Dow Jones report and Longeveron’s topline-results release directly support a new clinical outcome: the ELPIS II trial missed its Month-12 right ventricular ejection fraction (RVEF) primary endpoint, materially weakening the approval and future cash-flow prospects for the company’s lead program. The same announcement explicitly links cost conservation, an investment-bank-assisted strategic-options process, and FDA discussions to the result, so these are retained as related consequences within one development. The date is explicit as September 16, 2026, but no exact occurrence time is provided; the UTC timestamp is therefore date-normalized. Surprise is moderated because the FDA had previously questioned RVEF as an efficacy endpoint. Only LGVN is approved because the other listed companies are indirect, speculative read-throughs without a disclosed relationship or contract.
Longeveron initiated a process of exploring options to maximize shareholder value after a stem cell therapy to treat a heart condition in children failed to meet its primary endpoint in a Phase 2b trial.
The clinical-stage biotechnology company said Wednesday that laromestrocel did not meet the endpoint of improvement in right ventricular ejection fraction at month 12 for infants with hypoplastic left heart syndrome.
"The Company has initiated a process of optimizing cost containment and will explore all options with the goal of maximizing shareholder value," Longeveron said, adding that it plans to engage an investment bank as a strategic adviser and has begun implementing cash conservation measures.